Guidelines for the management of chronic kidney disease

New guidelines for the management of chronic kidney disease have been developed by the Canadian Society of Nephrology (Appendix 1 contains the full-text guidelines; available at [www.cmaj.ca/cgi/content/full/179/11/1154/DC1][1]). These guidelines describe key aspects of the management of chronic

[1]  S. Hernández-Díaz,et al.  Major congenital malformations after first-trimester exposure to ACE inhibitors. , 2006, The New England journal of medicine.

[2]  F. Holleman,et al.  Metformin and lactic acidosis: cause or coincidence? A review of case reports , 2004, Journal of internal medicine.

[3]  G. Chertow,et al.  Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. , 2004, Journal of the American Society of Nephrology : JASN.

[4]  K. Huttunen,et al.  Effects of three treatment modes on plasma lipids and lipoproteins in uraemic patients. , 1994, Annals of medicine.

[5]  C. Goldsmith,et al.  A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events , 2007, Diabetes Care.

[6]  Huiman Barnhart,et al.  Correction of anemia with epoetin alfa in chronic kidney disease. , 2006, The New England journal of medicine.

[7]  Bertram L Kasiske,et al.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Circulation.

[8]  F. McAlister,et al.  A novel process for updating recommendations for managing hypertension: rationale and methods. , 2000, The Canadian journal of cardiology.

[9]  R. Saracho,et al.  The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  E. Ritz,et al.  Low-dose calcitriol prevents the rise in 1,84-iPTH without affecting serum calcium and phosphate in patients with moderate renal failure (prospective placebo-controlled multicentre trial). , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  P. Whelton,et al.  Blood pressure and end-stage renal disease in men. , 1996, The New England journal of medicine.

[12]  G. Dailey,et al.  Effects of pulsatile intravenous insulin therapy on the progression of diabetic nephropathy. , 2000, Metabolism: Clinical and Experimental.

[13]  Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[14]  A. Levin,et al.  Comparative mortality of hemodialysis and peritoneal dialysis in Canada. , 2000, Kidney international.

[15]  W. Weintraub,et al.  Association of high serum creatinine and anemia increases the risk of coronary events: results from the prospective community-based atherosclerosis risk in communities (ARIC) study. , 2003, Journal of the American Society of Nephrology : JASN.

[16]  G. Eknoyan,et al.  Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  J. Stoves,et al.  A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[18]  Eld,et al.  COMPARISON OF MORTALITY IN ALL PATIENTS ON DIALYSIS , PATIENTS ON DIALYSIS AWAITING TRANSPLANTATION , AND RECIPIENTS OF A FIRST CADAVERIC TRANSPLANT , 2000 .

[19]  K. Iseki,et al.  Blood Pressure Predicts Risk of Developing End‐Stage Renal Disease in Men and Women , 2003, Hypertension.

[20]  Zhongxin Zhang,et al.  Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. , 2004, Kidney international.

[21]  B. Kestenbaum,et al.  Serum phosphate levels and mortality risk among people with chronic kidney disease. , 2005, Journal of the American Society of Nephrology : JASN.

[22]  S. Studenski,et al.  Clinical prognostic factors in lupus nephritis. The importance of hypertension and smoking. , 1992, Archives of internal medicine.

[23]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[24]  A. Garg,et al.  Prevalence of low glomerular filtration rate in nondiabetic Americans: Third National Health and Nutrition Examination Survey (NHANES III). , 2002, Journal of the American Society of Nephrology : JASN.

[25]  G. Devins,et al.  Predialysis psychoeducational intervention and coping styles influence time to dialysis in chronic kidney disease. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[26]  O. Samuelsson,et al.  Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis. , 1999, Kidney international.

[27]  S. Majumdar,et al.  Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[28]  G. Becker,et al.  The effect of protein restriction on the progression of renal insufficiency. , 1989, The New England journal of medicine.

[29]  David W. Johnson,et al.  Cost analysis of ongoing care of patients with end-stage renal disease: the impact of dialysis modality and dialysis access. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[30]  E. Zeitler,et al.  Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[31]  P. Bossuyt,et al.  Adjustment for comorbidity in studies on health status in ESRD patients: which comorbidity index to use? , 2003, Journal of the American Society of Nephrology : JASN.

[32]  L. Kuller,et al.  Lipid and blood pressure treatment goals for type 1 diabetes: 10-year incidence data from the Pittsburgh Epidemiology of Diabetes Complications Study. , 2001, Diabetes care.

[33]  Stephanie L. Brown,et al.  Peer mentoring: a culturally sensitive approach to end-of-life planning for long-term dialysis patients. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[34]  Marcello Tonelli,et al.  Hemodialysis clinical practice guidelines for the Canadian Society of Nephrology. , 2006, Journal of the American Society of Nephrology : JASN.

[35]  A. Caggiula.  Effects of dietary protein restriction on the progression of moderate renal disease in the Modification of Diet in Renal Disease Study. , 1996, Journal of the American Society of Nephrology : JASN.

[36]  K. Lancaster.  Dietary treatment of blood pressure in kidney disease. , 2004, Advances in chronic kidney disease.

[37]  H. Parving,et al.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. , 2001, The New England journal of medicine.

[38]  B. Kasiske.  Hyperlipidemia in patients with chronic renal disease. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[39]  R. Cooper,et al.  Association between chronic kidney disease and coronary artery calcification: the Dallas Heart Study. , 2005, Journal of the American Society of Nephrology : JASN.

[40]  H. Morita,et al.  RETRACTED: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial , 2003, The Lancet.

[41]  B. Davis,et al.  Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2005, Archives of internal medicine.

[42]  M. Schnitzler,et al.  CADAVERIC VERSUS LIVING DONOR KIDNEY TRANSPLANTATION , 1999 .

[43]  R. Swartz,et al.  CORE CURRICULUM IN NEPHROLOGY Palliative Care , 2004 .

[44]  R. R. Robinson.  Isolated proteinuria in asymptomatic patients. , 1980, Kidney international.

[45]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[46]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[47]  W. Duckworth,et al.  Factors affecting hypoglycemia awareness in insulin-treated type 2 diabetes: The Diabetes Outcomes in Veterans Study (DOVES). , 2004, Diabetes research and clinical practice.

[48]  G. Remuzzi,et al.  Preventing microalbuminuria in type 2 diabetes. , 2004, The New England journal of medicine.

[49]  Stephanie L. Brown,et al.  Palliative care in chronic kidney disease: peer mentoring program personalizes advance directives discussions. , 2003, Nephrology news & issues.

[50]  W. März,et al.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005, The New England journal of medicine.

[51]  H. Parving,et al.  Impact of Arterial Blood Pressure and Albuminuria on the Progression of Diabetic Nephropathy in IDDM Patients , 1993, Diabetes.

[52]  S. MacMahon,et al.  Effects of simvastatin and enalapril on serum lipoprotein concentrations and left ventricular mass in patients on dialysis. The Perfect Study Collaborative Group. , 1997, Journal of nephrology.

[53]  A. Donker,et al.  Protein restriction, glomerular filtration rate and albuminuria in patients with type 2 diabetes mellitus: a randomized trial , 2002, European Journal of Clinical Nutrition.

[54]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1993 .

[55]  M. Tonelli,et al.  Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. , 2007, JAMA.

[56]  M. Cooper,et al.  Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study , 2000, BMJ : British Medical Journal.

[57]  J. Holley.  PSYCHOSOCIAL FACTORS IN PATIENTS WITH CHRONIC KIDNEY DISEASE: Palliative Care in End‐Stage Renal Disease: Focus on Advance Care Planning, Hospice Referral, and Bereavement , 2005, Seminars in dialysis.

[58]  J. Kusek,et al.  Comorbidity assessment using the Index of Coexistent Diseases in a multicenter clinical trial. , 2001, Kidney international.

[59]  R. Klein,et al.  The association among smoking, heavy drinking, and chronic kidney disease. , 2006, American journal of epidemiology.

[60]  G. Jerums,et al.  A low-sodium diet potentiates the effects of losartan in type 2 diabetes. , 2002, Diabetes care.

[61]  R. Wilson,et al.  Prevalence of, and risk factors for, angiographically determined coronary artery disease in type I-diabetic patients with nephropathy. , 1992, Archives of internal medicine.

[62]  C. Decaestecker,et al.  Indirect evidence of glomerular/tubular mixed-type postexercise proteinuria in healthy humans. , 1988, The American journal of physiology.

[63]  J. Buring,et al.  Alcohol consumption and the risk of renal dysfunction in apparently healthy men. , 2005, Archives of internal medicine.

[64]  P. Raggi,et al.  Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. , 2007, Kidney international.

[65]  H. Parving,et al.  Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. , 2005, Kidney international.

[66]  K Doqi,et al.  clinical practice guidelines for chronic kidney disease : evaluation, classification, and stratification , 2002 .

[67]  W. Kannel,et al.  The prognostic significance of proteinuria: the Framingham study. , 1984, American heart journal.

[68]  Christopher H Schmid,et al.  Progression of Chronic Kidney Disease: The Role of Blood Pressure Control, Proteinuria, and Angiotensin-Converting Enzyme Inhibition: A Patient-Level Meta-Analysis , 2003, Annals of Internal Medicine.

[69]  Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic Hypertension , 1999 .

[70]  G. Beck,et al.  Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group. , 1995, Journal of the American Society of Nephrology : JASN.

[71]  G. Beck,et al.  Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. , 1997, Kidney international.

[72]  B. Manns,et al.  The impact of education on chronic kidney disease patients' plans to initiate dialysis with self-care dialysis: a randomized trial. , 2005, Kidney international.

[73]  S. Maggi,et al.  Atherosclerotic risk factors and renal function in the elderly: the role of hyperfibrinogenaemia and smoking. Results from the Italian Longitudinal Study on Ageing (ILSA). , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[74]  A. Levin,et al.  Multidisciplinary predialysis programs: quantification and limitations of their impact on patient outcomes in two Canadian settings. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[75]  Charles E McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[76]  L. Ruilope,et al.  Effects of body-weight loss and captopril treatment on proteinuria associated with obesity. , 1995, Nephron.

[77]  G. Beck,et al.  The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease , 1994 .

[78]  J. Schelling,et al.  A dipstick protein and specific gravity algorithm accurately predicts pathological proteinuria. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[79]  M. Rudnick,et al.  Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[80]  V. Manninen,et al.  Effects of hypertension and dyslipidemia on the decline in renal function. , 1995, Hypertension.

[81]  M. Lockhart,et al.  Effect of preoperative sonographic mapping on vascular access outcomes in hemodialysis patients. , 2001, Kidney international.

[82]  David Voss,et al.  Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. , 2004, Journal of the American Society of Nephrology : JASN.

[83]  S. Davison.  Facilitating advance care planning for patients with end-stage renal disease: the patient perspective. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[84]  R. Elashoff,et al.  Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. , 2000, The New England journal of medicine.

[85]  T. Greene,et al.  Blood Pressure Control, Proteinuria, and the Progression of Renal Disease , 1995, Annals of Internal Medicine.

[86]  M. Laakso,et al.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. , 1998, The New England journal of medicine.

[87]  M. Laville,et al.  Low protein diets delay end-stage renal disease in non-diabetic adults with chronic renal failure. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[88]  A. Laupacis,et al.  Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study , 2004 .

[89]  J. Lalau,et al.  Lactic Acidosis in Metformin-Treated Patients , 1999 .

[90]  G. Eknoyan,et al.  Bone metabolism and disease in chronic kidney disease , 2003 .

[91]  Mark E. Williams,et al.  Hemodialyzed type I and type II diabetic patients in the US: Characteristics, glycemic control, and survival. , 2006, Kidney international.

[92]  R. Gokal,et al.  Peritoneal Catheters and Exit-Site Practices toward Optimum Peritoneal Access: A Review of Current Developments , 2005, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[93]  Jonathan B. Brown,et al.  Lactic Acidosis Rates in Type 2 Diabetes , 1998, Diabetes Care.

[94]  Philip McFarlane,et al.  Multidisciplinary predialysis care and morbidity and mortality of patients on dialysis. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[95]  B. Davis,et al.  Cardiovascular Outcomes in High-Risk Hypertensive Patients Stratified by Baseline Glomerular Filtration Rate , 2006, Annals of Internal Medicine.

[96]  C. Giachelli.  Vascular calcification mechanisms. , 2004, Journal of the American Society of Nephrology : JASN.

[97]  S. Yusuf,et al.  Renal Insufficiency as a Predictor of Cardiovascular Outcomes and the Impact of Ramipril: The HOPE Randomized Trial , 2001, Annals of Internal Medicine.

[98]  Hude Quan,et al.  Adapting the Charlson Comorbidity Index for use in patients with ESRD. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[99]  Plamen Nikolov,et al.  Economic Costs of Diabetes in the U.S. in 2002 , 2003, Diabetes care.

[100]  W. Cattell,et al.  Proteinuria: Pathophysiology, Significance and Recommendations for Measurement in Clinical Practice , 1993, Annals of clinical biochemistry.

[101]  F. Dekker,et al.  When to initiate dialysis: effect of proposed US guidelines on survival , 2001, The Lancet.

[102]  G. Appel,et al.  The nephrotic syndrome, lipids, and risk factors for cardiovascular disease. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[103]  J. Rouleau,et al.  Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. , 2005, Journal of the American Society of Nephrology : JASN.

[104]  Serum erythropoietin concentration in chronic renal failure: relationship to degree of anemia and excretory renal function. , 1979 .

[105]  R M Hakim,et al.  Initiation of dialysis. , 1994, Advances in nephrology from the Necker Hospital.

[106]  H. Bloomfield,et al.  Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. , 2004, Kidney international.

[107]  P. Clavien,et al.  Kidney transplantation from donors without a heartbeat. , 2002, The New England journal of medicine.

[108]  Steven Snapinn,et al.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol , 2002, The Lancet.

[109]  M. Landray,et al.  First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[110]  M. Tonelli,et al.  The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients. , 2003, Kidney international.

[111]  Deanna J. M. Isaman,et al.  A computer simulation model of diabetes progression, quality of life, and cost. , 2005, Diabetes care.

[112]  S. Moe,et al.  Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[113]  N. Mittman,et al.  Predictive value of nutritional markers (albumin, creatinine, cholesterol, and hematocrit) for patients on dialysis for up to 30 years. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[114]  A. Zanchetti,et al.  Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. , 2001, Journal of the American Society of Nephrology : JASN.

[115]  K. Iseki,et al.  Relationship between predicted creatinine clearance and proteinuria and the risk of developing ESRD in Okinawa, Japan. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[116]  D. Swanson,et al.  Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy. , 2002, Archives of internal medicine.

[117]  Philip D. Harvey,et al.  Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39 , 1998, BMJ.

[118]  Yeong-Hoon Kim,et al.  Superior Patient Survival for Continuous Ambulatory Peritoneal Dialysis Patients Treated with a Peritoneal Dialysis Fluid with Neutral pH and Low Glucose Degradation Product Concentration (Balance) , 2005, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[119]  Angé,et al.  EFFECT OF THE USE OR NONUSE OF LONG-TERM DIALYSIS ON THE SUBSEQUENT SURVIVAL OF RENAL TRANSPLANTS FROM LIVING DONORS , 2001 .

[120]  C. Schmid,et al.  Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease , 2001, Annals of Internal Medicine.

[121]  H. Krum,et al.  Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis , 2007, The Lancet.

[122]  J. Bailey,et al.  Nutrition counseling impacts serum albumin levels. , 2004, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.

[123]  R. Minutolo,et al.  Salt Intake and Renal Outcome in Patients with Progressive Renal Disease , 1998, Mineral and Electrolyte Metabolism.

[124]  D. Churchill,et al.  Clinical practice guidelines for initiation of dialysis , 1999 .

[125]  Dario R Alessi,et al.  Metformin and reduced risk of cancer in diabetic patients , 2005, BMJ : British Medical Journal.

[126]  J. Craig,et al.  Meta-analysis of biochemical and patient-level effects of calcimimetic therapy. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[127]  P. Loirat,et al.  Role of Metformin Accumulation in Metformin-Associated Lactic Acidosis , 1995, Diabetes Care.

[128]  P. Eskildsen,et al.  Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[129]  A. Garg,et al.  Daily hemodialysis: a systematic review. , 2005, Clinical journal of the American Society of Nephrology : CJASN.

[130]  M. Ravid,et al.  Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications. , 2002, European journal of internal medicine.

[131]  M. Eriksson,et al.  Low-dose atorvastatin in severe chronic kidney disease patients: A randomized, controlled endpoint study , 2005, Scandinavian journal of urology and nephrology.

[132]  M. Coco,et al.  Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[133]  K. Farrington,et al.  Choosing Not to Dialyse: Evaluation of Planned Non-Dialytic Management in a Cohort of Patients with End-Stage Renal Failure , 2003, Nephron Clinical Practice.

[134]  S. Davison,et al.  Hope and advance care planning in patients with end stage renal disease: qualitative interview study , 2006, BMJ : British Medical Journal.

[135]  A D Oxman,et al.  Changing physician performance. A systematic review of the effect of continuing medical education strategies. , 1995, JAMA.

[136]  Hans L. Hillege,et al.  Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects With Microalbuminuria , 2004, Circulation.

[137]  M. Buset,et al.  Radioimmunoassay of erythropoietin in chronic uraemia or anephric patients. , 2009, Scandinavian journal of haematology.

[138]  L. Ruilope,et al.  Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. , 2004, The American journal of cardiology.

[139]  John H. Galla,et al.  Clinical practice guideline on shared decision-making in the appropriate initiation of and withdrawal from dialysis , 2000 .

[140]  Ping Wang,et al.  The Effect of Dietary Protein Restriction on the Progression of Diabetic and Nondiabetic Renal Diseases , 1996, Annals of Internal Medicine.

[141]  H. Parving,et al.  Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. , 2005, Diabetes care.

[142]  Detection.  The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) , 1997 .

[143]  P. Reichard,et al.  The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. , 1993, The New England journal of medicine.

[144]  David C. Murray,et al.  Outcome and risk factors of ischemic heart disease in chronic uremia. , 1996, Kidney international.

[145]  J. Adamson,et al.  Anemia of end-stage renal disease (ESRD). , 1985, Kidney international.

[146]  G. Beck,et al.  Frequent Hemodialysis Network (FHN) randomized trials: study design. , 2007, Kidney international.

[147]  K. Nordal,et al.  Low dose calcitriol versus placebo in patients with predialysis chronic renal failure. , 1988, The Journal of clinical endocrinology and metabolism.

[148]  J. Ordóñez‐Llanos,et al.  Triglyceride-rich lipoprotein abnormalities in CAPD-treated patients. , 1995, Nephrology, Dialysis and Transplantation.

[149]  R. Poveda,et al.  Goodpasture syndrome during the course of a Schönlein-Henoch purpura. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[150]  Y. Tsukamoto,et al.  Effect of administering calcium carbonate to treat secondary hyperparathyroidism in nondialyzed patients with chronic renal failure. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[151]  S. Stefoni,et al.  Early dialysis in renal substitutive programs. , 1978, Kidney international. Supplement.

[152]  F. Nuttall,et al.  Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators. , 2000, Diabetes care.

[153]  R. McPherson,et al.  Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. , 2006, The Canadian journal of cardiology.

[154]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[155]  A. Levin,et al.  Attitudes of Canadian nephrologists toward multidisciplinary team-based CKD clinic care. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[156]  S. Wild,et al.  Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. , 2004, Diabetes care.

[157]  S. Strandgaard,et al.  Exercise training and the progression of chronic renal failure. , 1997, Nephron.

[158]  汪关煜.  Renal osteodystrophy , 2002 .

[159]  B. Manns,et al.  Why patients with ESRD do not select self-care dialysis as a treatment option. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[160]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[161]  P Glasziou,et al.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.

[162]  G. Remuzzi,et al.  Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial , 2005, The Lancet.

[163]  K. Harris,et al.  The role of proteinuria in the progression of chronic renal failure. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[164]  S. Klahr.  The modification of diet in renal disease study. , 1989, The New England journal of medicine.

[165]  Christine A. White,et al.  Pre-dialysis clinic attendance improves quality of life among hemodialysis patients , 2002, BMC nephrology.

[166]  B. Zinman,et al.  Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. , 2005, The New England journal of medicine.

[167]  G. Remuzzi,et al.  Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. , 2003, Kidney international.

[168]  G. Bailie,et al.  Comparison of Intravenous Iron Sucrose to Oral Iron in the Treatment of Anemic Patients with Chronic Kidney Disease Not on Dialysis , 2005, Nephron Clinical Practice.

[169]  R. Mehta,et al.  Attitudes of Canadian Nephrologists toward Dialysis Modality Selection , 1999, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[170]  G. London,et al.  Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[171]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[172]  F Boomsma,et al.  Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. , 2006, Kidney international.

[173]  M. Chonchol,et al.  Effectiveness of a chronic kidney disease clinic in achieving K/DOQI guideline targets at initiation of dialysis--a single-centre experience. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[174]  G. Devins,et al.  Predialysis psychoeducational intervention extends survival in CKD: a 20-year follow-up. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[175]  S. Majumdar,et al.  Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin , 2006, Diabetes Care.

[176]  H. Malluche,et al.  1,25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial. , 1989, Kidney international.

[177]  W. Qunibi,et al.  Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). , 2004, Kidney international.

[178]  M. Lishner,et al.  Long-Term Stabilizing Effect of Angiotensin-Converting Enzyme Inhibition on Plasma Creatinine and on Proteinuria in Normotensive Type II Diabetic Patients , 1993, Annals of Internal Medicine.

[179]  A. Logan,et al.  The 2004 Canadian recommendations for the management of hypertension: Part III--Lifestyle modifications to prevent and control hypertension. , 2004, The Canadian journal of cardiology.

[180]  G. Navis,et al.  The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[181]  A. Morris,et al.  Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin , 2006, Diabetologia.

[182]  B. Zinman,et al.  Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. , 2006, The New England journal of medicine.

[183]  H. Meier‐Kriesche,et al.  Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: A Paired Donor Kidney Analysis1 , 2002, Transplantation.

[184]  Oluf Pedersen,et al.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. , 2003, The New England journal of medicine.

[185]  M. Tonelli,et al.  Statins for improving renal outcomes: a meta-analysis. , 2006, Journal of the American Society of Nephrology : JASN.

[186]  M. Elisaf,et al.  Lipid Parameters Including Lipoprotein (A) in Patients Undergoing CAPD and Hemodialysis , 1995, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[187]  P. Raggi,et al.  Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. , 2002, Kidney international.

[188]  David W. Johnson,et al.  The Initiating Dialysis Early and Late (Ideal) Study: Study Rationale and Design , 2004, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[189]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[190]  S. Yusuf,et al.  Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. , 2001, JAMA.

[191]  A. Harrower.  Pharmacokinetics of Oral Antihyperglycaemic Agents in Patients with Renal Insufficiency , 1996, Clinical pharmacokinetics.

[192]  G. Jhangri,et al.  Nephrologists' reported preparedness for end-of-life decision-making. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[193]  C. Price,et al.  Use of urine albumin measurement as a replacement for total protein. , 1995, Clinical nephrology.

[194]  F. Zannad,et al.  Effect of rosuvastatin on outcomes in chronic haemodialysis patients – design and rationale of the AURORA study , 2005, Current controlled trials in cardiovascular medicine.

[195]  M. Hediger,et al.  Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid , 1993, Nature.

[196]  D. de Zeeuw,et al.  Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. , 1989, Kidney international.

[197]  C. Price.  Resources for planning palliative and end-of-life care for patients with kidney disease. , 2003, Nephrology nursing journal : journal of the American Nephrology Nurses' Association.

[198]  W. Keane.  Lipids and the kidney. , 1994, Kidney international.

[199]  M. Emoto,et al.  Impact of Glycemic Control on Survival of Diabetic Patients on Chronic Regular Hemodialysis , 2006, Diabetes Care.

[200]  L. Stevens,et al.  Nephrology: 4. Strategies for the care of adults with chronic kidney disease. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[201]  Josef Coresh,et al.  Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. , 2003, Journal of the American Society of Nephrology : JASN.

[202]  G. Eknoyan,et al.  Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). , 2006, Kidney international.

[203]  Merlin C. Thomas,et al.  Unrecognized anemia in patients with diabetes: a cross-sectional survey. , 2003, Diabetes care.

[204]  P. Donohoe,et al.  End-of-life care in end-stage renal disease: renal and palliative care. , 2006, British journal of nursing.

[205]  J. Mclaughlin,et al.  Association between smoking and chronic renal failure in a nationwide population-based case-control study. , 2004, Journal of the American Society of Nephrology : JASN.

[206]  Mary Cushman,et al.  A prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort: the Cardiovascular Health Study. , 2005, Archives of internal medicine.

[207]  D. V. Van Wyck,et al.  A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. , 2005, Kidney international.

[208]  P. Stevens,et al.  Does urinary tract infection cause proteinuria or microalbuminuria? A systematic review. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[209]  E. Salpeter,et al.  Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. , 2003, The Cochrane database of systematic reviews.

[210]  B. Kanna,et al.  Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) study. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[211]  G. Remuzzi,et al.  Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). , 1998, Kidney international.

[212]  T. Koepsell,et al.  Glycemic control and the risk of multiple microvascular diabetic complications. , 2005, Family medicine.

[213]  Neil R. Powe,et al.  Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes. , 2007, Kidney international.

[214]  Kdoqi.  KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[215]  B. Kasiske,et al.  Preemptive kidney transplantation: the advantage and the advantaged. , 2002, Journal of the American Society of Nephrology : JASN.

[216]  K. Atsumi,et al.  Risk factors for vertebral fractures in renal osteodystrophy. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[217]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[218]  Kdoqi.  III. Clinical practice recommendations for anemia in chronic kidney disease in children. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[219]  L. Stevens,et al.  Detection of chronic kidney disease in non-nephrology practices: An important focus for intervention , 2005 .

[220]  D. Fedele,et al.  Evaluation of diagnostic reliability of DCA 2000 for rapid and simple monitoring of HbA1c , 2000, Acta Diabetologica.

[221]  G. Becker,et al.  Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[222]  Deeb N Salem,et al.  Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. , 2004, Journal of the American Society of Nephrology : JASN.

[223]  John S Yudkin,et al.  Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study , 2000, BMJ : British Medical Journal.

[224]  R. Bain,et al.  The urine protein to creatinine ratio as a predictor of 24-hour urine protein excretion in type 1 diabetic patients with nephropathy. The Collaborative Study Group. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[225]  Hemant,et al.  Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin. , 2003, The Journal of the Association of Physicians of India.

[226]  Bruce Kupelnick,et al.  K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease , 2004 .

[227]  M. Tonelli,et al.  A systematic review of the effect of nocturnal hemodialysis on blood pressure, left ventricular hypertrophy, anemia, mineral metabolism, and health-related quality of life. , 2005, Kidney international.

[228]  J L Botha,et al.  The British Diabetic Association Cohort Study, I: all‐cause mortality in patients with insulin‐treated diabetes mellitus , 1999, Diabetic medicine : a journal of the British Diabetic Association.

[229]  Caren Rose,et al.  Effectiveness of a multidisciplinary kidney disease clinic in achieving treatment guideline targets. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[230]  J. Meigs,et al.  Correlates of health-related quality of life in type 2 diabetes , 2006, Diabetologia.

[231]  P. Dupont,et al.  Lipid and apoprotein changes during atorvastatin up-titration in hemodialysis patients with hypercholesterolemia: a placebo-controlled study. , 2004, Clinical nephrology.

[232]  C. Whittle,et al.  The development of an Integrated Care Pathway for all patients with advanced life-limiting illness - the Supportive Care Pathway. , 2006, Journal of nursing management.

[233]  A. Doney,et al.  The effect of obesity on glycaemic response to metformin or sulphonylureas in Type 2 diabetes , 2006, Diabetic medicine : a journal of the British Diabetic Association.

[234]  J. Wootton.  Clinical practice guidelines. , 1999, Journal of women's health & gender-based medicine.

[235]  G. Beck,et al.  The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. , 1994, The New England journal of medicine.

[236]  M. Nieminen,et al.  Albuminuria and Cardiovascular Risk in Hypertensive Patients with Left Ventricular Hypertrophy: The LIFE Study , 2003, Annals of Internal Medicine.

[237]  Uk-Prospective-Diabetes-Study-Group.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[238]  Tom Greene,et al.  Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. , 2002, JAMA.

[239]  F. Collart,et al.  A Previously Undescribed Side Effect of Icodextrin: Overestimation of Glycemi a by Glucose Analyzer , 1998, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[240]  Ethan M Balk,et al.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[241]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[242]  Philip D. Harvey,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.

[243]  Rajnish Mehrotra,et al.  Patient education and access of ESRD patients to renal replacement therapies beyond in-center hemodialysis. , 2005, Kidney international.

[244]  A. Levin,et al.  Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. , 2007, Kidney international.

[245]  J. Bargman,et al.  Deterioration in renal function associated with fibrate therapy. , 2001, Clinical nephrology.

[246]  G. London,et al.  Arterial calcifications and bone histomorphometry in end-stage renal disease. , 2004, Journal of the American Society of Nephrology : JASN.

[247]  T. Nakao,et al.  Influence of erythropoietin treatment on hemoglobin A1c levels in patients with chronic renal failure on hemodialysis. , 1998, Internal medicine.

[248]  F. Kronenberg,et al.  Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients. , 2003, Kidney international. Supplement.

[249]  N. Powe,et al.  Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. , 2004, JAMA.

[250]  H. Parving,et al.  Beneficial impact of spironolactone in diabetic nephropathy. , 2005, Kidney international.

[251]  Daniel Levy,et al.  Predictors of new-onset kidney disease in a community-based population. , 2004, JAMA.

[252]  Kdoqi Disclaimer.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[253]  H. Tildesley,et al.  Metformin's contraindications should be contraindicated , 2005, Canadian Medical Association Journal.

[254]  H. Morrison,et al.  Hemodialysis versus peritoneal dialysis: a comparison of adjusted mortality rates. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[255]  G. Chertow,et al.  Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. , 2005, Kidney international.

[256]  David H. Smith,et al.  Effect of ergocalciferol supplementation on serum parathyroid hormone and serum 25‐hydroxyvitamin D in chronic kidney disease , 2006, Nephrology.

[257]  A. Tiengo,et al.  Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance , 2004, Diabetologia.

[258]  L. Arab,et al.  Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. , 2006, Kidney international.

[259]  T A Louis,et al.  A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[260]  S. Feasson,et al.  MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals : a randomised placebo-controlled trial. , 2008 .

[261]  J. Buring,et al.  Cholesterol and the risk of renal dysfunction in apparently healthy men. , 2003, Journal of the American Society of Nephrology : JASN.

[262]  Hospice.  National Consensus Project for Quality Palliative Care: Clinical Practice Guidelines for quality palliative care, executive summary. , 2004, Journal of palliative medicine.

[263]  G. Mancia,et al.  Clinical Outcomes in the Diabetes Cohort of the International Verapamil SR-Trandolapril Study , 2004, Hypertension.

[264]  R. Schmieder,et al.  Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. , 2005, Journal of the American Society of Nephrology : JASN.

[265]  L. Moist,et al.  DAILY HEMODIALYSIS—SELECTED TOPICS: An International Registry to Compare Quotidian Dialysis Regimens with Conventional Thrice‐Weekly Hemodialysis: Why, How, and Potential Pitfalls , 2004, Seminars in dialysis.

[266]  A. Morris,et al.  Contraindications to metformin therapy in patients with Type 2 diabetes—a population‐based study of adherence to prescribing guidelines , 2001, Diabetic medicine : a journal of the British Diabetic Association.

[267]  S. Davison,et al.  The creation of an advance care planning process for patients with ESRD. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[268]  J. Mckenney,et al.  National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2002 .

[269]  B. Hulme.  Dialysis and Renal Transplantation. , 1971, British medical journal.

[270]  M. Laville,et al.  Low protein diets for chronic kidney disease in non diabetic adults. , 2009, The Cochrane database of systematic reviews.

[271]  A. Luke,et al.  Obesity and prevalent and incident CKD: the Hypertension Detection and Follow-Up Program. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[272]  H. Bloomfield,et al.  Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[273]  M. Laville,et al.  Low protein diets for chronic kidney disease in non diabetic adults. , 2009, The Cochrane database of systematic reviews.

[274]  K. Iseki,et al.  Body mass index and the risk of development of end-stage renal disease in a screened cohort. , 2004, Kidney international.

[275]  H. Parving,et al.  Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. , 2002, Diabetes care.

[276]  G. Chertow,et al.  PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[277]  K. Iseki,et al.  Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. , 2002, Kidney international.

[278]  M. Massi-Benedetti.  The Cost of Diabetes Type II in Europe The CODE-2 Study , 2002, Diabetologia.

[279]  H. Clark,et al.  Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[280]  C. Schmid,et al.  Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. , 2001, Kidney international.

[281]  B W Gillespie,et al.  Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS. , 2006, Kidney international.

[282]  Bertram L Kasiske,et al.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Hypertension.

[283]  M. Saul,et al.  A simple comorbidity scale predicts clinical outcomes and costs in dialysis patients. , 2000, The American journal of medicine.

[284]  E. Morales,et al.  Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[285]  John Simes,et al.  Effect of Pravastatin on Cardiovascular Events in People With Chronic Kidney Disease , 2004, Circulation.

[286]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[287]  G. Beck,et al.  The Effect of a Lower Target Blood Pressure on the Progression of Kidney Disease: Long-Term Follow-up of the Modification of Diet in Renal Disease Study , 2005, Annals of Internal Medicine.

[288]  A. Levey,et al.  Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. , 1997, Annals of internal medicine.

[289]  A. Holstein,et al.  Contra‐indications to metformin therapy are largely disregarded , 1999, Diabetic medicine : a journal of the British Diabetic Association.

[290]  M. Pfeffer,et al.  Relation Between Serum Phosphate Level and Cardiovascular Event Rate in People With Coronary Disease , 2005, Circulation.

[291]  Carlos Iribarren,et al.  Body Mass Index and Risk for End-Stage Renal Disease , 2006, Annals of Internal Medicine.

[292]  Neil R. Powe,et al.  Lifestyle Factors, Obesity and the Risk of Chronic Kidney Disease , 2003, Epidemiology.

[293]  J. Berns,et al.  Reviews: Use of Insulin and Oral Hypoglycemic Medications in Patients with Diabetes Mellitus and Advanced Kidney Disease , 2004, Seminars in dialysis.

[294]  O. Djurdjev,et al.  The short- and long-term impact of multi-disciplinary clinics in addition to standard nephrology care on patient outcomes. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[295]  Philip J. Barter,et al.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[296]  G. Remuzzi,et al.  Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial , 1998, The Lancet.

[297]  M. Tonelli,et al.  Statins for Treatment of Dyslipidemia in Chronic Kidney Disease , 2006, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[298]  H. Malluche,et al.  Differences in bone turnover and intact PTH levels between African American and Caucasian patients with end-stage renal disease. , 2003, Kidney international.

[299]  J. Griffith,et al.  Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. , 2005, Journal of the American Society of Nephrology : JASN.

[300]  S. Klahr.  Prevention of progression of nephropathy. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[301]  P. Raggi,et al.  Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. , 2005, Kidney international.

[302]  D. Rush,et al.  Canadian Society of Transplantation consensus guidelines on eligibility for kidney transplantation , 2005, Canadian Medical Association Journal.

[303]  H. Parving,et al.  Progression of diabetic nephropathy. , 2001, Kidney international.

[304]  Matthew H Samore,et al.  Impact of timing of initiation of dialysis on mortality. , 2003, Journal of the American Society of Nephrology : JASN.

[305]  Essam Elsayed,et al.  Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[306]  S. Weisbord,et al.  Renal palliative care. , 2006, Journal of palliative medicine.

[307]  H. Morita,et al.  Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. , 2003, Lancet.

[308]  Ajay K. Singh,et al.  Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. , 2007, Journal of the American Society of Nephrology : JASN.

[309]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[310]  R. Bilous,et al.  Cause-specific mortality in a population with diabetes: South Tees Diabetes Mortality Study. , 2002, Diabetes care.

[311]  Maria C. Pruchnicki,et al.  Clinical pharmacists as multidisciplinary health care providers in the management of CKD: a joint opinion by the Nephrology and Ambulatory Care Practice and Research Networks of the American College of Clinical Pharmacy. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[312]  A. Levey,et al.  Effects of dietary protein restriction on the progression of moderate renal disease in the modification of diet in renal disease study: Modification of Diet in Renal Disease Study Group , 1996 .

[313]  F. Locatelli,et al.  Effect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency , 1996 .

[314]  P. Reichard,et al.  Nephropathy is delayed by intensified insulin treatment in patients with insulin‐dependent diabetes mellitus and retinopathy * , 1989, Journal of internal medicine.

[315]  S. Sprague,et al.  Impact of Ergocalciferol Treatment of Vitamin D Deficiency on Serum Parathyroid Hormone Concentrations in Chronic Kidney Disease , 2007, American Journal of Nephrology.

[316]  Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) , 1997, Lancet.

[317]  O. Samuelsson,et al.  Alterations in Lipoprotein Composition in Peritoneal Dialysis Patients , 2002, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[318]  J. Griffith,et al.  Lowest systolic blood pressure is associated with stroke in stages 3 to 4 chronic kidney disease. , 2007, Journal of the American Society of Nephrology : JASN.

[319]  D Hernández,et al.  Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH. , 1995, Kidney international.

[320]  M. Lishner,et al.  Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. , 1996, Archives of internal medicine.

[321]  The Gisen Group.  Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy , 1997, The Lancet.

[322]  L. Stevens,et al.  A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. , 2004, Kidney international.

[323]  W. Wołyniec,et al.  A single center experience in preemptive kidney transplantation. , 2006, Transplantation proceedings.

[324]  Giuseppe Remuzzi,et al.  Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria , 1999, The Lancet.

[325]  H. Burger,et al.  Normalization of hemoglobin level in patients with chronic kidney disease and anemia. , 2006, The New England journal of medicine.

[326]  J. Mustonen,et al.  Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. , 2004, The New England journal of medicine.

[327]  P. Goldwasser,et al.  Cholesterol and lipid disturbances in renal disease: the natural history of uremic dyslipidemia and the impact of hemodialysis and continuous ambulatory peritoneal dialysis. , 1989, The American journal of medicine.

[328]  C. Gullion,et al.  Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. , 2004, Archives of internal medicine.

[329]  R. Ferner,et al.  Comparative Tolerability Profiles of Oral Antidiabetic Agents , 1994, Drug safety.

[330]  C. Baigent,et al.  Study of Heart and Renal Protection (SHARP). , 2003, Kidney international. Supplement.

[331]  G. Spasovski,et al.  A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. , 2003, Kidney international. Supplement.

[332]  Lawrence A Leiter,et al.  The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy. , 2006, The Canadian journal of cardiology.

[333]  J. Manson,et al.  Association between body mass index and CKD in apparently healthy men. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[334]  Matthew D. Davis,et al.  Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. , 2000, The New England journal of medicine.

[335]  M. Tonelli,et al.  Association between multidisciplinary care and survival for elderly patients with chronic kidney disease. , 2007, Journal of the American Society of Nephrology : JASN.

[336]  J. Singer,et al.  Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[337]  L. Irwig,et al.  Feasibility study of the early detection and treatment of renal disease by mass screening , 2002, Internal medicine journal.

[338]  D. Wheeler,et al.  A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD. , 2002, Kidney international.

[339]  E. Brown,et al.  Supportive care for the renal patient. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[340]  W. Min,et al.  Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[341]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[342]  淳一 佐々木.  Air Force/Texas Coronary Atherosclerosis Prevention Study , 2008 .

[343]  P. Macfarlane,et al.  West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trials , 1996 .

[344]  Y. Berland,et al.  A randomized trial of low-protein diet in type 1 and in type 2 diabetes mellitus patients with incipient and overt nephropathy. , 2005, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.

[345]  B. Dimitrov,et al.  Long-Term Outcome of Renal Transplantation from Older Donors , 2006 .

[346]  G. Eknoyan,et al.  Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[347]  D. de Zeeuw,et al.  Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[348]  L. Schurgers,et al.  Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. , 2004, Journal of the American Society of Nephrology : JASN.

[349]  N. Chaturvedi.  Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. , 2001, Annals of internal medicine.

[350]  Kdoqi Disclaimer,et al.  KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[351]  T. A. Jacobson,et al.  Statin safety: lessons from new drug applications for marketed statins. , 2006, The American journal of cardiology.

[352]  E. Araki,et al.  Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. , 1995, Diabetes research and clinical practice.

[353]  M. Tonelli,et al.  Impact of anemia on hospitalization and mortality in older adults. , 2006, Blood.

[354]  J. Lalau,et al.  Lactic acidosis in metformin therapy: searching for a link with metformin in reports of ‘metformin‐associated lactic acidosis’ , 2001, Diabetes, obesity & metabolism.

[355]  M. Stolar.  Clinical Management of the NIDDM Patient: Impact of the American Diabetes Association Practice Guidelines, 1985–1993 , 1995, Diabetes Care.

[356]  D. Wesson,et al.  Cigarette smoking is associated with augmented progression of renal insufficiency in severe essential hypertension. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[357]  T. Greene,et al.  Relationship between nutritional status and the glomerular filtration rate: results from the MDRD study. , 2000, Kidney international.